AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Isomorphic Labs says it is preparing to begin human trials of drugs designed with its AlphaFold-based AI platform.

The DeepMind spinoff has spent the past year expanding hiring, funding, and partnerships to support drug development.

If the trials work, they could help validate AI as a faster, more precise way to discover and design medicines.

A successful result would mark a major step toward using AI to accelerate treatments for serious diseases.